Hill­e­Vax's stock tum­bles af­ter Phase 2b norovirus vac­cine fails in in­fants

Take­da spin­out Hill­e­Vax’s stock $HLVX sunk over 85% on Mon­day morn­ing af­ter the com­pa­ny an­nounced its norovirus vac­cine can­di­date failed a …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.